Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 60Terminated 17Withdrawn 5Recruiting 5Unknown 4Active not recruiting 4No longer available 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma, Non-Hodgkin 12Myelodysplastic Syndromes 11Recurrence 7Leukemia, Myelomonocytic, Chronic 7Anemia, Refractory, with Excess of Blasts 7Leukemia, Biphenotypic, Acute 6Multiple Myeloma 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma 5Hodgkin Disease 5Hematologic Neoplasms 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Burkitt Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3Melanoma 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma, B-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Colorectal Neoplasms 3Breast Neoplasms 3Blastic Plasmacytoid Dendritic Cell Neoplasm 3Triple Negative Breast Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2

Interventions

Rituximab 41Cyclophosphamide 37Magnetic Resonance Spectroscopy 22Specimen Handling 20Prednisone 19Doxorubicin 19polatuzumab vedotin 18Lenalidomide 17Biopsy 15fludarabine 13Oxaliplatin 13Gemcitabine 13Vincristine 12zanubrutinib 11Immunotherapy, Adoptive 11Etoposide 10glofitamab 8obinutuzumab 7axicabtagene ciloleucel 7Prednisolone 7ibrutinib 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Leukapheresis 6Injections 6Ifosfamide 6CT-P10 6Bendamustine Hydrochloride 6orelabrutinib 5loncastuximab tesirine 5fludarabine phosphate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Large B-Cell, Diffuse × fludarabine phosphate × Clear all
NCT06500273 2026-05-20

ALPHA3

Allogene Therapeutics

Phase 2 Recruiting
250 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT06026319 2026-03-16

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Massachusetts General Hospital

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04545762 2026-01-14

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco

Phase 1 Recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06550141 2025-11-14

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Massachusetts General Hospital

Phase 2 Recruiting
28 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05052528 2024-05-13

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

University of California, Davis

Phase 1 Recruiting
36 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡